Lyell to Highlight Vision for Its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

GlobeNewswireJan 9 22:00

Bank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)

TipRanksJan 6 19:37 · Ratings

Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4

Futu NewsDec 24, 2024 21:32 · Ratings

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Zacks Dec 13, 2024 21:40

Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma

BarchartDec 10, 2024 20:26

Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024

BenzingaDec 10, 2024 14:58